The Questions Families Ask

When ovarian or peritoneal cancer keeps coming back, families ask the same questions: what the treatment terms mean, what a trial involves, how long, what happens next, and how to prepare. Plain answers, with the evidence.

Line by Line described the drugs used against high-grade cancer of the ovary, fallopian tube and peritoneum, and why each tends to work for less time than the one before. This companion is for the people around a patient once the cancer has come back more than once: partners, children, friends. It answers the questions they tend to ask, in roughly the order they ask them, and says what the evidence shows and where it stops.

It is general. No two patients are the same, and the people who know a particular case are the patient and her medical team; every section ends, in effect, with a question to take to them. It describes what studies have found; it is not medical advice. Some of it is hard to read. It is written on the view that most families would rather know.

6months: the usual line between platinum-sensitive and platinum-resistant recurrence

11months: median survival of women with platinum-resistant cancer treated outside trials, in one large series

0survival gained by starting treatment as soon as the blood marker CA-125 rises

16%with depressive symptoms with early palliative care, against 38% without, in a lung cancer trial

The vocabulary

Where are we? Lines and platinum

Doctors describe the course of treatment in lines. A line is one treatment plan with medicines, from the day it starts until it stops, usually because the cancer has grown again. Several drugs given together are one line, and so are all their cycles. Surgery is not a line. Two rules confuse families most: maintenance treatment after chemotherapy, such as a PARP inhibitor or bevacizumab, counts as part of the line before it; and a drug changed because of side effects, without the cancer growing, does not start a new line. The number of lines matters because clinical trials often set limits on it.

The second piece of vocabulary is platinum. Carboplatin, the drug at the heart of the first treatment, is the most effective drug against these cancers, and when the cancer comes back the first question is how long it has been since the last dose. Six months or more, and the cancer is called platinum-sensitive: platinum usually works again. Less, and it is platinum-resistant, and platinum is usually set aside. Line by Line explains why cancers become resistant.

Families often ask whether “platinum-resistant” means the disease will now move fast. Partly. The label already describes speed, since it means the cancer came back within six months; and the treatments that follow are weaker. In the main trials in platinum-resistant cancer, the median time until the cancer grew again was three to four months on standard chemotherapy and about five to eight months with the newer combinations.[1][2][3] But it is not a cliff edge. These are medians, the spread is wide, and some cancers keep moving slowly. And the six-month line measures time, not mechanism: in an Australian study, women with an inherited BRCA mutation responded more often at relapse, to platinum and to other drugs, even when the cancer had come back early.[4]

Two further points come up often. Doctors sometimes “save” platinum for later, using another drug first. There can be good reasons, such as an allergy to carboplatin or nerve damage from paclitaxel, but doing it simply to lengthen the interval does not help: in the MITO-8 trial, women whose cancer returned six to twelve months after platinum did better with platinum first.[5] And a rising blood marker, CA-125, is a warning rather than an instruction. In the MRC OV05 trial, 529 women whose CA-125 rose after a complete response were randomised to start treatment at once or to wait for symptoms; survival was the same (median 25.7 against 27.1 months).[6]

A trial is proposed

What a clinical trial involves

New treatments are tested in phases. Phase 1 trials, with few patients, ask whether a drug is safe and at what dose; phase 2 trials whether it shows signs of working; phase 3 trials, with hundreds of patients, whether it is better than the current standard. In a phase 3 trial patients are usually randomised, and in cancer trials the comparison group receives the standard treatment, not nothing. Reaching phase 3 does not mean the drug is known to be better: that is what the trial is for. After several lines, phase 1 and phase 2 trials are often offered, because they give earlier access to new drugs and often accept more earlier lines; phase 3 is not automatically the better option.

Being offered a trial is not the same as being in it. First comes screening: a recent scan with at least one deposit large enough to measure, blood tests, an assessment of general fitness, sometimes a tumour sample tested for a marker the drug targets, and a count of earlier treatments. Many ovarian cancer trials also exclude women with bowel obstruction; AURELIA, for example, excluded those with a history of it.[1] Not qualifying reflects the trial’s rules, not how serious the disease is. Joining means written consent after a full explanation, with the right to leave at any time without losing normal care, and closer follow-up.

A trial’s public record can be alarming: start dates years ago, completion years ahead, hundreds of patients. Those dates are for the whole study. For one patient, the timescale is weeks (Figure 1).

Fig. 1 — One patient’s time in a clinical trial: a few weeks of screening, then treatment on the trial’s schedule (often every three weeks) for as long as it helps, with scans every six to nine weeks. A schematic; schedules differ between trials. Trials can be looked up by name or number on ClinicalTrials.gov and the European register.[7]

The hardest question

How long?

This is the question most families want answered and fewest ask. The honest answer has three parts: what studies show for groups of patients, how widely individuals vary around that, and what only the patient’s own doctors can add.

Figure 2 puts the main numbers side by side. In platinum-sensitive relapse, survival is often counted in years: in the SOLO2 trial of women with a BRCA mutation, median survival was 38.8 months with placebo and 51.7 with olaparib.[8] In platinum-resistant disease, the recent trials found medians of about 12 to 18 months from the start of a new treatment.[3][2][9] Those trials took fit patients after one to three earlier lines; outside trials, results are worse. In 176 women with platinum-resistant cancer treated with bevacizumab and chemotherapy in routine care, median survival was 11 months.[10] When the disease itself blocks the bowel, the outlook shortens further: median survival from the first episode was about five and a half months in 73 women and about three months in 22, with a very wide range.[11][12]

Fig. 2 — Median overall survival in different situations, in months. Black: control group; pink: new treatment; teal: single series. The studies measured from different starting points (entry to a trial, start of treatment, first bowel obstruction) and enrolled different patients, so the chart shows orders of magnitude, not comparisons. Sources: Poveda et al. 2021; Lorusso et al. 2026; Moore et al. 2023; FDA 2026; the real-world and bowel-obstruction series cited in the text.

Turned into broad ranges for four common situations, the evidence looks like Figure 3. These are judgements drawn from the medians above, not calculations, and they are meant to show the scale of each situation, not to predict anyone’s course.

Fig. 3 — Broad ranges for four situations, in months from the start of each: darker for the most likely range, lighter for what is possible. Judgements from the published medians in Figure 2; a minority of patients fall outside them in both directions.

Any single number would be false precision, because survival around a median is very spread out. Figure 4 shows a smooth curve with a median of twelve months: about a quarter of patients have died by five months, and about a quarter are still alive at two years. Real curves are lumpier, but the spread is of that kind.

Fig. 4 — How spread out survival is around a median: an illustrative curve with a median of 12 months, not data from any study.

What narrows the range is what the patient’s doctors know: whether the current treatment is working, whether bowel problems come from the disease, how well she eats and manages daily life, and how long each previous treatment held the disease. Poor nutrition, weight loss and low fitness predicted shorter survival in women with bowel obstruction.[13] Doctors are often willing to answer a plain question, if the patient wants it asked: “If you had to estimate, are we talking about months or years? What would change that?” Some patients want that conversation and some do not; both are legitimate.

The bowel

Adhesions or the disease

Repeated abdominal problems are common at this stage, and families are often told two different explanations. Adhesions are bands of scar tissue left by surgery; after the large operations these cancers often require, they are likely, and they can kink the bowel and cause partial blockages years later. The disease itself can also block the bowel, as deposits narrow it, press on it or stop it moving. Both can be present at once, and from outside the symptoms look the same: cramps, swelling, nausea, vomiting, little stool or gas.

Doctors tell them apart from scans, which can show where the bowel narrows and whether there is tumour at that point, though not always conclusively, and from the course: a blockage that settles quickly with bowel rest and stays away fits adhesions; repeated, worsening episodes alongside growing disease fit the cancer. In one study of women with advanced disease followed for about seven years after surgery, small-bowel obstruction occurred in 24–42%, and most episodes were partial and managed without an operation.[14] The distinction matters for treatment and for outlook; for trial eligibility it matters less, since most trials exclude obstruction whatever its cause.

When to call the team at once

Repeated vomiting, a swollen or very tight belly, cramping pain, no stool or gas, fever during treatment, sudden swelling of one leg, or sudden breathlessness.

What to expect

How symptoms usually progress

In this cancer most of the trouble happens inside the abdomen, because that is where the disease grows. Changes usually come in steps rather than a straight line: a problem appears, it is treated, and things settle for a while. Much of it can be eased.

• Between treatments, earlier on: few or vague symptoms, such as tiredness, mild bloating or changes in bowel habit; often a rising marker or a scan change comes first, and a new line starts.
• Fluid in the abdomen (ascites): a swollen, tight belly, early fullness, sometimes breathlessness. Drainage with a needle brings relief within hours; a permanent small drain can be placed if the fluid keeps returning, so it can be drained at home.
• The bowel: cramps after meals, alternating constipation and diarrhoea, then episodes of partial obstruction, as above.
• Appetite and weight: eating less is partly mechanical and partly the illness changing the body’s metabolism; small frequent meals, supplements and a dietitian help for a while.
• Pain: usually abdominal; regular pain relief, including morphine-type drugs when needed, works well and, used properly, does not shorten life.
• Less often: fluid around a lung, swollen legs, blood clots, or pressure on the tubes that drain the kidneys, which can be relieved with stents.

When the bowel is blocked repeatedly or persistently, it is often a turning point. The options then are medicines that reduce secretions, vomiting and cramps; a venting tube that drains the stomach, so that the patient is not vomiting and can still taste food; surgery or a stent in carefully selected cases; and intravenous feeding, which is a real decision to weigh with the team. In a series of 40 such patients, those selected for palliative surgery lived longer after it, but the groups differed, and frailty and poor nutrition predicted worse outcomes.[13] At this stage, cancer treatment is weighed against the burden it adds, and the patient’s own judgement matters most.

In the last weeks there is usually more sleep, less eating and drinking, and growing weakness, with changes in breathing near the very end. Palliative care teams, at home or in a unit, are expert at keeping that time calm: pain, nausea, breathlessness and agitation can all be treated.

Early, not late

Palliative care is not the end

Many families hear “palliative care” as giving up. It is not: it is a specialist team for symptoms, decisions and support, and it can work alongside any cancer treatment, a trial included. The best-known test of starting it early was in lung cancer. In 151 patients with metastatic disease, those who saw a palliative care team from diagnosis had better quality of life, fewer depressive symptoms (16% against 38%) and less aggressive care at the end of life, and they lived longer, a median of 11.6 months against 8.9.[15] That was a different cancer and a single trial, so the survival difference should not be over-read; but the case for asking for palliative care early, rather than waiting, is strong. Asking for it is a reasonable request at any consultation.

Preparing

Preparing, as a family

What follows is practical guidance of the kind palliative care and psycho-oncology teams give; it is general, and every family will adapt it.

With the patient, first. Talk about what she wants, at her pace: where she would like to be cared for, what she would and would not want if she could no longer decide, how and by whom her children should be told. Patients often try to protect everyone around them; saying out loud that it is possible to talk usually helps. In Portugal, wishes can be written down as an advance directive (testamento vital) and a healthcare proxy (procurador de cuidados de saúde) can be named to decide if she cannot, under Law 25/2012.[16] Registration in the national register, RENTEV, is free; the document is signed in person at a RENTEV desk or sent with a notarised signature.[17]

With the children, including young adults. They sense more than they are told, and being kept outside usually hurts more than the truth. Tell them honestly, at the level they ask for, and keep telling them as things change; agree with the patient how far they are included, since some want to come to consultations and others want to know without every detail. Avoid making one of them the main confidant or carer: they need to remain her children and keep their own lives, and carrying on with studies, work and friends is not abandonment. Expect different reactions, closeness, withdrawal, anger: grief often starts early. Ordinary time, a meal, a walk, a film, is often what they remember most.

Practical steps. Ask early for the palliative care team; see the hospital’s social worker about leave from work, care at home, equipment and paperwork; keep one place with the team’s numbers, the medication list and who to call at night. In Portugal, the Liga Portuguesa Contra o Cancro runs a support line, the Linha Cancro (808 255 255), with information and psychological and social support for patients and families,[18] and hospital psycho-oncology services usually see family members too.

The carer. The person who organises, explains and keeps the mood light needs someone to talk to as well. Nobody can hold everyone up if nobody holds them up.

For the consultation

Questions to take to the team

About where things stand: how many lines of treatment have there been, by the trials’ rules? Is the cancer considered platinum-sensitive or platinum-resistant now? Is the current treatment working, and what will the next scan show us? Is the disease growing faster than before?

About a proposed trial: what is its name and number, and which phase? What is being compared, and what would she receive outside it? What did earlier phases show, especially side effects? Does she need a tumour test? How long from screening to treatment? What happens if she is not eligible, or it does not work?

About the body: are the abdominal problems adhesions, disease, or both? What should make us call, and whom do we call at night or at weekends?

About the future: if you had to estimate, months or years? What would change that? Can we be referred to the palliative care team now, alongside treatment?

The balance

What is known and what is not

Known. Platinum resistance usually means shorter control with each treatment, and survival counted in months to a year or two rather than years, with wide variation. Bowel obstruction caused by the disease shortens the outlook further. Starting treatment on a rising marker alone does not lengthen life. Early palliative care improved quality of life in a randomised trial, and did not shorten it. Most symptoms at this stage can be eased.

Not known. How any one patient will fare: the studies describe groups. How well results from trials, which select fit patients with fewer earlier lines, apply after many lines. Whether early palliative care helps ovarian cancer patients as it helped those with lung cancer; the large trials were in other cancers. And the numbers here will age: new treatments were approved in 2026, and survival in the next trials may be longer.

On method and tools

This guide was researched and written with Claude Opus 5.5 (Anthropic): human specification, editorial direction and critical review; machine research, drafting and figure generation. The subject was Luis’s choice. Every study cited was checked against its PubMed record, and the figures and quotations come from the abstracts; the KEYNOTE-B96 figures come from the FDA’s announcement, and the Portuguese legal and support information from the official pages cited. The ranges in the second figure are judgements drawn from the published medians, not calculations, and the curve in the third figure is an illustration with a 12-month median, not data; the figures are drawn by scripts/questions.py, and the values are listed in docs/questions-results.json. The descriptions of how symptoms progress and the guidance on preparing as a family summarise standard palliative care and psycho-oncology practice; they are general, not drawn from the studies cited. The cover is a drawing, not data. This guide describes what studies have found; it is not medical advice.

Authored by: Luis Matos Ferreira — Physicist, Developer, Writer

Related essays on this blog

1. Line by Line — the drugs for these cancers, from platinum to antibody-drug conjugates, and why platinum stops working.
2. The Inner Lining — cancers of the peritoneum, and what surgery with heated chemotherapy can do.
3. The Brakes Released — cancer immunotherapy: checkpoint drugs, CAR-T cells and vaccines.

Sources

1. E. Pujade-Lauraine, F. Hilpert, B. Weber et al., “Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial”, Journal of Clinical Oncology 32, 1302–1308 (2014), doi.org.
2. K. N. Moore, A. Angelergues, G. E. Konecny et al., “Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer”, The New England Journal of Medicine 389, 2162–2174 (2023), doi.org.
3. D. Lorusso, L. Gladieff, D. M. O'Malley et al., “Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial”, Lancet (London, England) 407, 1513–1524 (2026), doi.org.
4. K. Alsop, S. Fereday, C. Meldrum et al., “BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group”, Journal of Clinical Oncology 30, 2654–2663 (2012), doi.org.
5. M. C. Piccirillo, G. Scambia, A. Bologna et al., “Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer”, Annals of Oncology 29, 1189–1194 (2018), doi.org.
6. G. J. Rustin, M. E. van der Burg, C. L. Griffin et al., “Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial”, Lancet (London, England) 376, 1155–1163 (2010), doi.org.
7. ClinicalTrials.gov, the public register of clinical studies, clinicaltrials.gov; and the EU Clinical Trials Information System, euclinicaltrials.eu.
8. A. Poveda, A. Floquet, J. A. Ledermann et al., “Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial”, The Lancet Oncology 22, 620–631 (2021), doi.org.
9. US Food and Drug Administration, “FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma”, 10 February 2026, with the KEYNOTE-B96 results (page consulted 4 November 2026), fda.gov.
10. G. T. Moffat, W. Kong, H. J. MacKay et al., “Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer”, Gynecologic Oncology 184, 51–56 (2024), doi.org.
11. J. Jansen, E. Oldenburger, J. Jansen et al., “Bowel obstruction in advanced tubo-ovarian cancer: a retrospective cohort study”, Annals of Medicine and Surgery 85, 1539–1545 (2023), doi.org.
12. P. Martinez Castro, L. Vargas, A. Mancheño et al., “Malignant Bowel Obstruction in Relapsed Ovarian Cancer With Peritoneal Carcinomatosis: An Occlusive State”, International Journal of Gynecological Cancer 27, 1367–1372 (2017), doi.org.
13. A. Daniele, A. Ferrero, L. Fuso et al., “Palliative care in patients with ovarian cancer and bowel obstruction”, Supportive Care in Cancer 23, 3157–3163 (2015), doi.org.
14. L. F. Falla-Zuniga, A. Sardi, M. C. King et al., “Small bowel obstruction and ovarian cancer: insights from a propensity-score matched study in patients with and without hyperthermic intraperitoneal chemotherapy after cytoreductive surgery”, World Journal of Surgical Oncology 23, 318 (2025), doi.org.
15. J. S. Temel, J. A. Greer, A. Muzikansky et al., “Early palliative care for patients with metastatic non-small-cell lung cancer”, The New England Journal of Medicine 363, 733–742 (2010), doi.org.
16. Lei n.º 25/2012, de 16 de julho, on advance directives (testamento vital) and the healthcare proxy, and creating the RENTEV register, diariodarepublica.pt.
17. gov.pt, “Registar o Testamento Vital” (page consulted 4 November 2026), gov.pt.
18. Liga Portuguesa Contra o Cancro, support services and the Linha Cancro, 808 255 255 (hours and conditions to be checked on the site), ligacontracancro.pt.